MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 90.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,860 shares of the company’s stock after purchasing an additional 2,783 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Contineum Therapeutics were worth $86,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Legal & General Group Plc raised its position in Contineum Therapeutics by 74.0% in the 4th quarter. Legal & General Group Plc now owns 3,631 shares of the company’s stock worth $53,000 after buying an additional 1,544 shares during the last quarter. Corebridge Financial Inc. grew its stake in shares of Contineum Therapeutics by 73.1% during the 4th quarter. Corebridge Financial Inc. now owns 5,215 shares of the company’s stock valued at $76,000 after purchasing an additional 2,202 shares during the period. MetLife Investment Management LLC bought a new stake in shares of Contineum Therapeutics during the 4th quarter valued at about $103,000. Rhumbline Advisers grew its stake in shares of Contineum Therapeutics by 36.3% during the 4th quarter. Rhumbline Advisers now owns 8,233 shares of the company’s stock valued at $121,000 after purchasing an additional 2,191 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Contineum Therapeutics by 63.4% during the 4th quarter. Bank of America Corp DE now owns 9,132 shares of the company’s stock valued at $134,000 after purchasing an additional 3,542 shares during the period.

Contineum Therapeutics Trading Up 21.0%

Shares of NASDAQ:CTNM opened at $4.43 on Tuesday. The stock has a 50 day moving average of $4.51 and a 200 day moving average of $8.79. The company has a market cap of $114.61 million and a PE ratio of -2.25. Contineum Therapeutics, Inc. has a 12-month low of $3.35 and a 12-month high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Equities research analysts predict that Contineum Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on CTNM. Royal Bank of Canada restated an “outperform” rating and set a $31.00 price target on shares of Contineum Therapeutics in a research note on Thursday, May 15th. Robert W. Baird cut their price target on Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, March 7th. Jones Trading assumed coverage on Contineum Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $23.00 price target for the company. Finally, Morgan Stanley cut their price objective on Contineum Therapeutics from $25.00 to $20.00 and set an “overweight” rating for the company in a research note on Monday, May 19th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Contineum Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $22.50.

Contineum Therapeutics Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).